Prestige Consumer Healthcare (PBH) Depreciation & Amortization (CF) (2010 - 2025)
Prestige Consumer Healthcare (PBH) recorded quarterly Depreciation & Amortization (CF) of $7.6 million in Q4 2025, down 0.93% quarter-over-quarter from $7.7 million in Q3 2025, and up 10.54% on a YoY basis from $6.9 million in Q4 2024.
Prestige Consumer Healthcare (PBH) Depreciation & Amortization (CF) (2010 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Depreciation & Amortization (CF) history runs 16 years deep, the most recent figure standing at $7.6 million for Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 10.54% year-over-year to $7.6 million; the TTM figure through Dec 2025 stood at $30.2 million (down 1.92% YoY), while the FY2025 annual figure was $30.2 million, down 1.64% from the prior year.
- Depreciation & Amortization (CF) was $7.6 million for Q4 2025 at Prestige Consumer Healthcare, down from $7.7 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $8.5 million in Q1 2022 to a low of $6.9 million in Q4 2024.
- Historically, Depreciation & Amortization (CF) has averaged $7.8 million across 5 years, with a median of $7.8 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) gained 12.58% in 2022, then fell 10.18% in 2024.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $8.0 million in 2021, then gained by 0.99% to $8.1 million in 2022, then retreated by 5.95% to $7.6 million in 2023, then dropped by 10.18% to $6.9 million in 2024, then grew by 10.54% to $7.6 million in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $7.6 million (Q4 2025), $7.7 million (Q3 2025), and $7.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Prestige Consumer Healthcare | 2.37 Bn | 2.31 Bn | 157.37 Mn | 7.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.59 Mn |
| Dec 31, 2025 | 7.59 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Jun 30, 2025 | 7.67 Mn |
| Jun 30, 2025 | 7.67 Mn |
| Mar 31, 2025 | 7.25 Mn |
| Mar 31, 2025 | 7.25 Mn |
| Dec 31, 2024 | 6.87 Mn |
| Dec 31, 2024 | 6.87 Mn |
| Sep 30, 2024 | 7.93 Mn |
| Sep 30, 2024 | 7.93 Mn |
| Jun 30, 2024 | 8.12 Mn |
| Jun 30, 2024 | 8.12 Mn |
| Mar 31, 2024 | 7.84 Mn |
| Mar 31, 2024 | 7.84 Mn |
| Dec 31, 2023 | 7.65 Mn |
| Dec 31, 2023 | 7.65 Mn |
| Sep 30, 2023 | 7.64 Mn |
| Sep 30, 2023 | 7.64 Mn |